Background: Transmembrane proteins of the CD44 family play roles in cell-cell and cell-matrix interactions, and their aberrant expression has been reported to be associated with the growth and metastasis of various tumors. The authors examined CD44 standard (CD44st) and CD44 variant 6 (CD44v6) expression in extrahepatic bile duct (EHBD)/ampullary carcinoma.
Methods: In 36 EHBD/ampullary carcinomas, immunohistochemical analyses with monoclonal antibodies against the human CD44st protein or CD44v6 protein were performed by the streptavidin-biotin immunoperoxidase method. The relation between expression of the proteins and lymph node metastases or patient outcome was investigated. To verify the lack of CD44v6 mRNA expression in tumors negative for CD44v6 staining, reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot hybridization were performed.
Results: Immunohistochemical analyses revealed that 13 of 36 carcinomas (36.1%) expressed the CD44v6 protein. Only 2 of 13 CD44v6-expressing primary tumors (15.4%) had regional lymph node metastases, whereas 14 of 23 tumors showing no CD44v6 expression (60.9%) had lymph node metastases (Fisher exact test, P<0.01). Moreover, a lack of CD44v6 expression was correlated significantly with poor prognosis (generalized Wilcoxon test, P<0.05). Eleven of 13 CD44v6 positive tumors showed CD44st expression, which also was correlated with prognosis. RT-PCR and Southern blot hybridization revealed a lack of CD44v6 mRNA expression in the tumors that were negative for CD44v6 staining.
Conclusions: The results of the current study suggest that a lack of expression of CD44, especially CD44v6, is correlated with lymph node metastases and poor prognosis, and may be a prognostic factor for patients with EHBD/ampullary carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Risk of Lymph Node Metastasis in T2 Colon Cancer: A Nationwide Population-Based Cohort Study.
Ann Surg Oncol
January 2025
Department of Gastroenterology and Hepatology, Isala, Zwolle, The Netherlands.
Background: Similar to T1 colon cancer (CC), risk stratification may guide T2 CC treatment and reduce unnecessary major surgery. In this study, prediction models were developed that could identify T2 CC patients with a lower risk of lymph node metastasis (LNM) for whom (intensive) follow-up after local treatment could be considered.
Methods: A nationwide cohort study was performed involving pT2 CC patients who underwent surgery between 2012 and 2020, using data from the Dutch ColoRectal Audit, which were linked to the Nationwide Pathology Databank.
Positive lateral lymph node turned negative after neoadjuvant therapy-surgery or observation?
Tech Coloproctol
January 2025
Department of Surgery, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
Since the adoption of neoadjuvant chemoradiation and total mesorectal excision as the standard in rectal cancer care, there has been marked improvement in the local recurrence rates. In this context, restaging magnetic resonance imaging (MRI) plays a key role in the assessment of tumor response, occasionally enabling organ-sparing approaches. However, the role of restaging MRI in evaluating lateral lymph nodes remains limited.
View Article and Find Full Text PDFWho is a candidate at the initial presentation? Prediction of positive lateral lymph node and survival after dissection.
Tech Coloproctol
January 2025
Department of Colorectal Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpodearo, Seochogu, Seoul, 06591, Korea.
Metastatic lateral pelvic lymph node (LPN) in rectal cancer has a significant clinical impact on the prognosis and treatment strategies. But there are still debates regarding prediction of lateral pelvic lymph node metastasis and its oncological impact. This review explores the evidence for predicting lateral pelvic lymph node metastasis and survival in locally advanced rectal cancer.
View Article and Find Full Text PDFReversed anatomy in transanal lateral lymph node dissection: landmarks and pitfalls.
Tech Coloproctol
January 2025
Department of Colorectal Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Lateral lymph node dissection (LLND) is getting global attention as an a surgical option to reduce local recurrence in locally advanced rectal cancer. As the transanal total mesorectal excision (TaTME) is gaining popularity worldwide, a novel LLND approach was established adopting a two-team approach that combines the transabdominal and transanal approaches using the TaTME technique. This narrative review describes the advantages, anatomical landmarks, surgical techniques, and pitfalls of transanal LLND (TaLLND).
View Article and Find Full Text PDFThe oncologic benefits of lateral lymph node dissection after neoadjuvant therapy - local control or survival?
Tech Coloproctol
January 2025
Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Port Road, SA, 5000, Australia.
Lateral pelvic lymph node dissection (LPLND) for rectal adenocarcinoma is an established treatment modality for selected patients with abnormal lateral pelvic lymph nodes on magnetic resonance imaging (MRI) imaging. The goal of this treatment is to achieve a true R0 resection, including lymphadenectomy, with the aim of improving patient oncological outcome, potentially at the expense of surgical and functional complications. However, there remain several areas of controversy resulting from a distinct lack of clarity regarding effective patient selection, lymph node size criteria, the role and extent of routine neoadjuvant treatment versus surgery alone in selected cases, the impact on patient survival metrics and whether the existing data are even valid in the era of total neoadjuvant therapy (TNT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!